Health Bulletin 11/November/2023

Here are the top health stories for the day:

NBE grants final opportunity for registration to 2021, 2022 batch trainees

The National Board of Examinations (NBE) has given one Final Opportunity for Registration with NBEMS for trainees of the 2021 and 2022 Admission Session

After joining a seat for an NBEMS course, the trainee is registered with the NBEMS for training in respective course for the entire duration of the course.

The eligibility of the trainee for said NBEMS programme is determined on the basis of prescribed criteria in the information bulletin for respective entrance examination. On successfully meeting the criteria and submission of required application with prescribed documents to NBEMS, the trainee gets registered with NBEMS. A letter to this effect in form of a “Letter of Provisional Registration” is communicated to the trainee and his/her training institution.

For more details, check out the link given below:

NBE Grants Final Opportunity For Registration To 2021, 2022 Batch Trainees, Details

Ozempic side effects 'well-known', Novo Nordisk argues

Novo Nordisk has refuted a Louisiana woman’s claim that her doctors weren’t properly warned of the side effects of the company’s blockbuster drug Ozempic, saying the vomiting and pain she alleged to have experienced are documented side effects included on the drug's label.

The Danish drugmaker filed a motion to dismiss Jaclyn Bjorklund’s lawsuit against the company on Friday in Louisiana federal court. Bjorklund said that while taking the drug for Type 2 Diabetes she developed gastroparesis, a slowdown in the emptying of the stomach into the small intestine, that led to her vomiting and pain.

For more details, check out the link given below:

Ozempic Side Effects 'Well-Known', Novo Nordisk Argues

US approves highly anticipated Eli Lilly weight loss drug

Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Zepbound (tirzepatide) injection, an obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis.

For more details, check out the link given below:

Eli Lilly Bags USFDA Nod For Zepbound Injection For Weight Loss